Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
2009 StandoutScience
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
2011
Amino acid pattern and glutamate metabolism during dehydration stress in the 'resurrection' plant Sporobolus stapfianus: a comparison between desiccation-sensitive and desiccation-tolerant leaves
2007 StandoutNobel
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer
2003
Protein nanoparticles as drug carriers in clinical medicine
2008
Epigenetics: A Landscape Takes Shape
2007 Standout
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Plants as a source of anti-cancer agents
2005 Standout
Histone deacetylase inhibitors – a new tool to treat cancer
2004
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Horizontal Gene Transfer from Diverse Bacteria to an Insect Genome Enables a Tripartite Nested Mealybug Symbiosis
2013 Standout
Epigenetic therapy of cancer: past, present and future
2006
Histone methylation: a dynamic mark in health, disease and inheritance
2012 Standout
Effects of plants and microorganisms in constructed wetlands for wastewater treatment
2003 Standout
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
2007
Emerging roles of proteases in tumour suppression
2007
The Epigenomics of Cancer
2007 Standout
Research advances in ethanol metabolism
2001
Epigenetics in Cancer
2008 Standout
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Epigenetics in cancer
2009 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
2008 Standout
Protease-Activated Drug Development
2012
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Integration of EGFR inhibitors with radiochemotherapy
2006
Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy
2008
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
2004
Antioxidants, Oxidative Damage and Oxygen Deprivation Stress: a Review
2002 Standout
Histone deacetylase inhibitors in clinical development
2004
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Phosphorus acquisition and use: critical adaptations by plants for securing a nonrenewable resource
2003 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
The emerging roles of human tissue kallikreins in cancer
2004
Neurobiology of addiction: a neurocircuitry analysis
2016 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Environmental epigenomics and disease susceptibility
2007 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Chromatin, cancer and drug therapies
2008
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
2009
Multiple lateral gene transfers and duplications have promoted plant parasitism ability in nematodes
2010
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
Review: Practical considerations in ovarian cancer chemotherapy
2010
Alcohol Metabolism and Cardiovascular Response in an Alcoholic Patient Homozygous for theALDH2*2Variant Gene Allele
1999
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
Global Histone Modifications Predict Prognosis of Resected Non–Small-Cell Lung Cancer
2007
Root exudates as mediators of mineral acquisition in low-nutrient environments
2002 Standout
Comparison of sucrose metabolism during the rehydration of desiccation‐tolerant and desiccation‐sensitve leaf material of Sporobolus stapfianus
2004
OXYGEN DEFICIENCY AND ROOT METABOLISM: Injury and Acclimation Under Hypoxia and Anoxia
1997
Sunflower trypsin inhibitor (SFTI-1) analogues of synthetic and biological origin via N→S acyl transfer: potential inhibitors of human Kallikrein-5 (KLK5)
2014 StandoutNobel
THE ORGANIZATION AND REGULATION OF PLANT GLYCOLYSIS
1996
Climate change associated effects on grape and wine quality and production
2010 Standout
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Epigenetic regulation of redox state mediates persistent cardiorespiratory abnormalities after long‐term intermittent hypoxia
2016 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Differential Regulation of Enolase during Anaerobiosis in Maize
1998
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of A. S. Williams being referenced
Phase I Study of Oral CI-994 in Combination with Carboplatin and Paclitaxel in the Treatment of Patients with Advanced Solid Tumors
2004
Identification and Gene Expression of Anaerobically Induced Enolase in Echinochloa phyllopogon and Echinochloa crus-pavonis
1995
Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer
2003
An A/G Polymorphism in the Promoter of Mitochondrial Aldehyde Dehydrogenase (ALDH2): Effects of the Sequence Variant on Transcription Factor Binding and Promoter Strength
1999
Purification, Properties and Phosphorylation of Anaerobically Induced Enolase in <italic>Echinochloa phyllopogon</italic> and <italic>E. crus-pavonis</italic>
1995
Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer
2007
Pectolytic and Cellulolytic Enzymes of Two Populations of Ditylenchus dipsaci on 'Wando' Pea (Pisum sativum L.).
1970
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
2005
Characterization of a Novel Prostate-Specific Antigen–Activated Peptide-Doxorubicin Conjugate in Patients With Prostate Cancer
2002